4.5 Article

Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2

期刊

ACS MEDICINAL CHEMISTRY LETTERS
卷 6, 期 6, 页码 695-700

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acsmedchemlett.5b00124

关键词

Epigenetics; SMYD2; H3K36; p53; methyltransferase; lysine

资金

  1. AbbVie [1097737]
  2. SGC
  3. Bayer [1097737]
  4. Boehringer Ingelheim [1097737]
  5. Genome Canada through Ontario Genomics Institute [OGI- 055]
  6. GlaxoSmithKline [1097737]
  7. Janssen [1097737]
  8. Lilly Canada [1097737]
  9. Novartis Research Foundation [1097737]
  10. Ontario Ministry of Economic Development and Innovation [1097737]
  11. Pfizer [1097737]
  12. Takeda [1097737]
  13. Wellcome Trust [1097737, 092809/Z/10/Z]

向作者/读者索取更多资源

A lack of useful small molecule tools has precluded thorough interrogation of the biological function of SMYD2, a lysine methyltransferase with known tumor-suppressor substrates. Systematic exploration of the structure activity relationships of a previously known benzoxazinone compound led to the synthesis of A-893, a potent and selective SMYD2 inhibitor (IC50: 2.8 nM). A cocrystal structure reveals the origin of enhanced potency, and effective suppression of p53K370 methylation is observed in a lung carcinoma (A549) cell line.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据